Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

Inventiva is going all-in on its metabolic-associated steatohepatitis (MASH) drug lanifibranor —but half of its employees won ...

A Comprehensive, Evidence-Based Review of GLP-1/GIP Agonists for Fitness and Wellness Professionals ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...